DK3653049T5 - Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse - Google Patents

Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse Download PDF

Info

Publication number
DK3653049T5
DK3653049T5 DK19204021.0T DK19204021T DK3653049T5 DK 3653049 T5 DK3653049 T5 DK 3653049T5 DK 19204021 T DK19204021 T DK 19204021T DK 3653049 T5 DK3653049 T5 DK 3653049T5
Authority
DK
Denmark
Prior art keywords
polynucleotides encoding
animals including
rodent antibodies
human idiotypes
encoding rodent
Prior art date
Application number
DK19204021.0T
Other languages
English (en)
Other versions
DK3653049T3 (da
Inventor
Marianne Bruggemann
Roland Buelow
Michael J Osborn
Biao Ma
Original Assignee
Omniab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50935093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3653049(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omniab Inc filed Critical Omniab Inc
Publication of DK3653049T3 publication Critical patent/DK3653049T3/da
Application granted granted Critical
Publication of DK3653049T5 publication Critical patent/DK3653049T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK19204021.0T 2012-12-14 2013-12-13 Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse DK3653049T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737371P 2012-12-14 2012-12-14
EP13843056.6A EP2931030B2 (en) 2012-12-14 2013-12-13 Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same

Publications (2)

Publication Number Publication Date
DK3653049T3 DK3653049T3 (da) 2023-11-13
DK3653049T5 true DK3653049T5 (da) 2024-08-26

Family

ID=50935093

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19204021.0T DK3653049T5 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse
DK13843056.6T DK2931030T4 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13843056.6T DK2931030T4 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse

Country Status (20)

Country Link
US (2) US9475859B2 (da)
EP (3) EP4269602A3 (da)
JP (1) JP6705650B2 (da)
KR (3) KR20220041953A (da)
CN (2) CN104994729B (da)
AU (2) AU2013358958B2 (da)
CA (1) CA2895144C (da)
CY (1) CY1123215T1 (da)
DK (2) DK3653049T5 (da)
ES (2) ES2963516T3 (da)
FI (2) FI2931030T4 (da)
HR (2) HRP20201160T4 (da)
HU (2) HUE050930T2 (da)
IL (2) IL239300B (da)
LT (2) LT3653049T (da)
PL (2) PL3653049T3 (da)
PT (2) PT3653049T (da)
SG (1) SG11201504676VA (da)
SI (2) SI2931030T2 (da)
WO (1) WO2014093908A2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2398882C2 (ru) 2004-07-22 2010-09-10 Эрасмус Юниверсити Медикал Сентр Роттердам СПОСОБ ПОЛУЧЕНИЯ АНТИГЕН-СВЯЗЫВАЮЩЕГО ДОМЕНА Vh ИСПОЛЬЗОВАНИЕ
US10993420B2 (en) * 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
CN114774466A (zh) 2014-10-22 2022-07-22 克雷森多生物制剂有限公司 转基因小鼠
WO2016100819A1 (en) * 2014-12-19 2016-06-23 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
US10669343B2 (en) 2015-08-05 2020-06-02 Janssen Biotech, Inc. Anti-CD154 antibodies and methods of using them
AU2016308567B2 (en) 2015-08-17 2022-10-27 Janssen Biotech, Inc. Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof
MA43053A (fr) 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
CA3003899A1 (en) 2015-11-02 2017-05-11 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
SI3462853T1 (sl) 2016-06-03 2023-05-31 Regeneron Pharmaceuticals, Inc. Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo
CA3029209A1 (en) * 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
PL4050034T3 (pl) * 2016-09-14 2024-07-22 Teneoone, Inc. Przeciwciała wiążące cd3
WO2018095932A1 (en) * 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
EP3544998A1 (en) * 2016-11-22 2019-10-02 Merck Patent GmbH Monoclonal antibody directed to fgfr1
KR20190104400A (ko) * 2017-01-19 2019-09-09 오픈 모노클로날 테크놀로지, 인코포레이티드 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
CN117567624A (zh) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
EP3642237A2 (en) 2017-06-20 2020-04-29 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
SG11202005880XA (en) 2017-12-22 2020-07-29 Teneobio Inc Heavy chain antibodies binding to cd22
EP3752530A1 (en) 2018-02-14 2020-12-23 ABBA Therapeutics AG Anti-human pd-l2 antibodies
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
BR112020023026A2 (pt) 2018-05-11 2021-02-09 WuXi Biologics Ireland Limited anticorpos completamente humanos contra ox40, método para a sua preparação e sua utilização
US12012461B2 (en) 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
KR20210011999A (ko) 2018-05-24 2021-02-02 얀센 바이오테크 인코포레이티드 단일특이성 및 다중특이성 항-tmeff2 항체 및 이의 용도
US11603405B2 (en) 2018-05-24 2023-03-14 Janssen Biotech, Inc. Anti-CD3 antibodies and uses thereof
JP7182647B2 (ja) 2018-06-14 2022-12-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫グロブリン重鎖コーディング配列におけるｄｈ－ｄｈ再構成が可能な非ヒト動物
WO2020169022A1 (en) 2019-02-18 2020-08-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animals with humanized immunoglobulin locus
AU2020291938A1 (en) 2019-06-14 2022-01-20 Teneobio, Inc. Multispecific heavy chain antibodies binding to CD22 and CD3
WO2021019389A1 (en) 2019-07-26 2021-02-04 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
CN118515779A (zh) 2019-07-26 2024-08-20 詹森生物科技公司 抗hk2嵌合抗原受体（car）
CN114746119A (zh) 2019-09-27 2022-07-12 詹森生物科技公司 抗-ceacam抗体及其用途
KR20220091497A (ko) 2019-10-03 2022-06-30 얀센 바이오테크 인코포레이티드 서열 최적화에 의해 안정성이 증가된 바이오의약품의 제조 방법
AU2020395122A1 (en) 2019-12-02 2022-06-09 Regeneron Pharmaceuticals, Inc. Peptide-MHC II protein constructs and uses thereof
AU2021263448A1 (en) 2020-04-29 2022-11-24 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
MX2022014938A (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
EP4158034A4 (en) 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals Beijing Co Ltd GENETICALLY MODIFIED NON-HUMAN ANIMALS HAVING A LIGHT-CHAIN IMMUNOGLOBULIN LOCUS
MX2023001256A (es) 2020-07-29 2023-05-16 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
US20220195014A1 (en) 2020-12-23 2022-06-23 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
EP4284446A2 (en) 2021-01-27 2023-12-06 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2023081705A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
IL314495A (en) 2022-01-26 2024-09-01 Janssen Biotech Inc Immunoconjugates comprising kallikrein-related antigen peptidase 2 binding sites and uses thereof
WO2024064714A2 (en) 2022-09-21 2024-03-28 Seagen Inc. Antibodies that bind cd228
WO2024064713A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
US5411881A (en) 1990-07-10 1995-05-02 Nkk Corporation Chicken-specific immunoglobulin G-producing hybridoma
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK0814159T3 (da) * 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2338791T3 (es) 1992-08-21 2010-05-12 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
PT1500329E (pt) * 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
RU2398882C2 (ru) 2004-07-22 2010-09-10 Эрасмус Юниверсити Медикал Сентр Роттердам СПОСОБ ПОЛУЧЕНИЯ АНТИГЕН-СВЯЗЫВАЮЩЕГО ДОМЕНА Vh ИСПОЛЬЗОВАНИЕ
WO2006047603A2 (en) * 2004-10-22 2006-05-04 Revivicor, Inc. Ungulates with genetically modified immune systems
RU2435784C2 (ru) 2006-01-25 2011-12-10 Эрасмус Юниверсити Медикал Сентр Роттердам Получение антител из одних тяжелых цепей в трансгенных животных
EP2003960B1 (en) * 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2336329T3 (da) * 2007-06-01 2013-01-07 Omt Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunglobulingener og til produktion af transgene, humane, idiotypiske antistoffer
EP2792236B2 (en) 2009-07-08 2023-03-22 Kymab Limited Animal models and therapeutic molecules
EP2582230A1 (en) 2010-06-17 2013-04-24 Kymab Limited Animal models and therapeutic molecules
EP2638155A1 (en) 2010-11-08 2013-09-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination

Also Published As

Publication number Publication date
DK2931030T3 (da) 2020-08-03
HRP20201160T1 (hr) 2020-12-11
US10385132B2 (en) 2019-08-20
CN104994729A (zh) 2015-10-21
EP4269602A3 (en) 2023-12-27
ES2963516T3 (es) 2024-03-27
IL239300B (en) 2021-01-31
EP3653049B1 (en) 2023-09-13
CN104994729B (zh) 2019-01-11
AU2013358958B2 (en) 2018-09-20
AU2018223041A1 (en) 2018-09-20
SI2931030T1 (sl) 2020-10-30
KR20210040189A (ko) 2021-04-12
SI2931030T2 (sl) 2024-06-28
SI3653049T1 (sl) 2024-02-29
KR20150094720A (ko) 2015-08-19
EP2931030B2 (en) 2024-01-17
DK2931030T4 (da) 2024-04-22
CA2895144C (en) 2024-04-16
KR102239125B1 (ko) 2021-04-12
AU2018223041B2 (en) 2020-06-25
WO2014093908A3 (en) 2014-10-16
PT2931030T (pt) 2020-08-03
PL2931030T5 (pl) 2024-06-10
SG11201504676VA (en) 2015-07-30
WO2014093908A2 (en) 2014-06-19
US9475859B2 (en) 2016-10-25
ES2813609T3 (es) 2021-03-24
FI2931030T4 (fi) 2024-04-22
DK3653049T3 (da) 2023-11-13
JP6705650B2 (ja) 2020-06-03
US20150113668A1 (en) 2015-04-23
FI3653049T3 (fi) 2023-11-02
LT3653049T (lt) 2023-11-10
NZ749259A (en) 2020-09-25
IL239300A0 (en) 2015-07-30
CA2895144A1 (en) 2014-06-19
HRP20231356T1 (hr) 2024-02-16
PL3653049T3 (pl) 2024-02-26
EP2931030B1 (en) 2020-04-29
HUE064063T2 (hu) 2024-02-28
PL2931030T3 (pl) 2021-03-22
EP3653049A1 (en) 2020-05-20
LT2931030T (lt) 2020-11-10
CN110042105A (zh) 2019-07-23
HUE050930T2 (hu) 2021-01-28
PT3653049T (pt) 2023-11-14
JP2016505257A (ja) 2016-02-25
KR20220041953A (ko) 2022-04-01
IL279716A (en) 2021-01-31
EP2931030A2 (en) 2015-10-21
AU2013358958A1 (en) 2015-07-09
HRP20201160T4 (hr) 2024-10-11
ES2813609T5 (es) 2024-08-09
CN110042105B (zh) 2023-03-28
NZ709608A (en) 2020-09-25
US20170174770A1 (en) 2017-06-22
CY1123215T1 (el) 2021-12-31
EP4269602A2 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
DK3653049T3 (da) Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse
DK3308641T3 (da) Immundeficient genmodificeret gnaver og fremgangsmåder til anvendelse deraf
DK2844672T3 (da) Humane antistoffer over for Fel d1 og fremgangsmåder til anvendelse deraf
DK3083688T3 (da) Humane anti-cd40 humane antistoffer
BR112013021785A8 (pt) animais geneticamente modificados e métodos para fazer os mesmos
DK3300745T3 (da) Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
EP2863736A4 (en) GENETICALLY MODIFIED ANIMALS AND METHODS OF PRODUCTION THEREFOR
DK3071593T3 (da) Modificerede humane t-celle-receptorer med høj affinitet
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
BR112014029053A2 (pt) disposição de escovação e método de operação de disposição de escovação animal.
BR302013006798S1 (pt) Configuração aplicada em halter.
DK3431492T3 (da) Humane cd30-ligandantigen-bindende proteiner
DK2967018T3 (da) Apparat og fremgangsmåde til indfangning af akvatiske dyr
DK2994900T3 (da) System til dyresundhedsovervågning
DK3046412T3 (da) Histidin-manipulerede letkæde-antistoffer og genetisk modificerede ikke-humane dyr til generering heraf
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK3016547T3 (da) Dyrebarriere og fremgangsmåde
DK2814843T3 (da) IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
BR112015008902A2 (pt) métodos de geração de animais geneticamente superiores.
GB201306076D0 (en) Animal trap
BR112015010316A2 (pt) materiais biocompostos derivados de proteínas animais
GB2509299B (en) An animal trap
BR302012005516S1 (pt) Configuração aplicada em casinha de animais
TH1401003793A (th) การวิเคราะห์สำหรับการจำแนกชนิดของสัตว์ในสภาวะดิบและที่ปรุงสุกแล้ว
GB2506356B (en) An animal deterrent